Risk Stratification and Benefits With Cardiac Resynchronization Therapy (CRT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

154 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study to learn which patients benefit from CRT therapy and to track the clinical changes that help identify the risk-level of CRT patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D

NCT00453622

Heart Failure

COMPLETED

Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients

NCT04083690

Heart Failure, Systolic

UNKNOWN NA

Ensure Cardiac Resynchronization Therapy Study

NCT00291564

Heart Failure

COMPLETED

Resynchronization/Defibrillation for Ambulatory Heart Failure Trial

NCT00251251

Heart Failure, Congestive

COMPLETED NA

Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients

NCT01466621

Heart Failure Pacing Induced Dyssynchrony

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is two-fold. First, to determine if an algorithm can be developed based on pre-implant clinical variables to predict response to CRT-D therapy. Second, the study aims to determine in patients implanted with CRT-D if the combined use of cTnT and BNP can further predict and risk-stratify HF improvement and all-cause mortality. Additionally, novel biochemical markers defining cardiac mortality in high risk patients detected by plasma proteomic analysis in the CRT-D patients will be evaluated.

This study represents a combination of previous CRT studies that evaluated these variables independently. Data from this study will be pooled with data from previous studies to build a more complete picture of CRT therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Ventricular Arrhythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CRT device-recipients

CRT device implant

Intervention Type DEVICE

CRT device-recipients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CRT device implant

CRT device-recipients

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets current clinical indications for CRT-D therapy
* Patient is 18 years old or older
* Ability to independently comprehend and complete all QOL questionnaires
* Patient has the ability to perform the 6-minute Hall Walk Test (6-MHW) with the only limiting factor being fatigue or shortness-of-breath
* Ability to provide informed consent for a study and be willing and able to comply with the prescribed follow-up

Exclusion Criteria

* Inability to successfully implant an intravascular lead and CRT-D device. (i.e. exclude epicardial leads) within 30 days of initial procedure.
* Myocardial infarction in the last 3 weeks
* Unstable angina in the last 3 weeks
* Status 1 classification for cardiac transplantation
* Currently participating in a clinical trial that includes an active treatment arm
* Life expectancy of less than 12 months.
* Recent (within 1 week) administration of Nesiritide™ or inotropes
* Patients in whom revascularization is expected
* Patient is pregnant

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No